Education
About Us
Working with TipRanks
Follow Us
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
CGTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $1.29
Previous CloseN/A
Volume950.02K
Average Volume (3M)14.01M
Market Cap
$63.09M
Enterprise Value$8.60M
Total Cash (Recent Filing)$16.43M
Total Debt (Recent Filing)$635.00K
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Nov 12, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding73,472,200
10 Day Avg. Volume3,302,591
30 Day Avg. Volume14,011,799
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-128.38
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
$3.00Price Target Upside248.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 2 'START' study for Alzheimer's disease has surpassed 50% enrollment, marking steady progress in the trial.
Financial SupportThe START Study's partnership with the Alzheimer's Clinical Trials Consortium and $81M grant support from the National Institute of Aging bolster its financial foundation.
Regulatory ProgressThe application for Breakthrough Therapy Designation for zervimesine in dementia with Lewy bodies could significantly boost Cognition Therapeutics' prospects.
Bears Say
Development TimelinePotential delays in reaching full enrollment for the Phase 2 'START' study could affect the anticipated top-line data availability.
Market CompetitionThe competitive landscape in Alzheimer's and dementia treatment markets poses challenges to Cognition Therapeutics' market positioning.
Regulatory UncertaintyAwaiting formal regulatory feedback introduces uncertainty that could impact Cognition Therapeutics' clinical development timelines.
Cognition Therapeutics News
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.22 and its highest was $1.29 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $63.09M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 91 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.105 by -$0.005.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 73,472,200 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.105. Following the earnings report the stock price went up 10.294%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Among the largest hedge funds holding Cognition Therapeutics’s share is Carlson Capital LP. It holds Cognition Therapeutics’s shares valued at 0.
Cognition Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (248.84% Upside)
$3.00 (248.84% Upside)
Blogger Sentiment
Bearish
CGTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 140.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.85%
12-Months-Change
Fundamentals
Return on Equity
-219.68%
Trailing 12-Months
Asset Growth
-42.91%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of neurodegenerative diseases, such as Alzheimer's disease and other central nervous system disorders. The company's core product candidates are small molecule therapeutics designed to target synaptic dysfunction by modulating key protein interactions involved in the pathology of these diseases.
CGTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress in clinical efficacy signals and strategic cost management, extending the cash runway. However, challenges remain with increased net losses, NASDAQ compliance issues, and uncertain funding partnerships. The sentiment is balanced by advancements in manufacturing and patent filings.View all CGTX earnings summariesCGTX Stock 12 Month Forecast
Average Price Target
$3.00
▲(248.84% Upside)
Technical Analysis
Ownership Overview
22.66% Insiders
2.48% Mutual Funds
0.07% Other Institutional Investors
72.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---